Streptococcus pneumoniae Antibodies, IgG (9 Serotypes)
Ordering Recommendation
Quantitative Multiplex Bead Assay
Tue, Fri
1-5 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Serum separator tube. Post-immunization specimen should be drawn 30 days after immunization and, if shipped separately, must be received within 60 days of pre-immunization specimen.  
Specimen Preparation
Separate serum from cells within 2 hours of collection. Transfer 1.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL) MARK SPECIMENS CLEARLY AS "PRE" OR "POST" SO SPECIMENS WILL BE SAVED AND TESTED SIMULTANEOUSLY.  
Storage/Transport Temperature
Refrigerated. "Pre" and "post" pneumococcal vaccine specimens can be submitted separately or together for testing.  
Unacceptable Conditions
Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens.  
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)  
Reference Interval
Interpretive Data
A pre-and post-vaccination sample comparison is required in order to assess the humoral immune response to vaccination with Streptococcus pneumonia vaccine. Post vaccination samples should be obtained at 4 weeks post-immunization. A single sample provides only general immune status of an individual to various serotypes of pneumococci. Immune response to pneumococci may vary in different individuals based on the age, vaccination status, immunologic competence and the serotype of the organism. Long-term protection is generally considered to be a serotype antibody level of 1.3 µg/ mL or greater.

Following vaccination, an antibody ratio of less than twofold is considered a non-responder; a ratio of two-to fourfold is a weak responder; a ratio of fourfold or greater is a good responder. The higher the pre-vaccination antibody level for a specific pneumococcal serotype, the less likely the response will increase significantly after vaccination.

An increased antibody level to 50-70 percent or more of the serotypes is thought to represent a normal humoral response. In the case of pure polysaccharide vaccine, indication of immune system competence is further delineated as an adequate response to at least 70 percent of the serotypes in the vaccine challenge for those 6-65 years of age, or to at least 50 percent of the serotypes in the vaccine challenge for those 2-5 years of age.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Includes Serotypes 2, 10A, 11A, 15B, 17F, 19A, 20, 22F, and 33F. (Conjugated Serotypes: 19A.).

This assay is designed to use both pre- and post-immunization specimens to assess immune responsiveness to pneumococcal vaccine. This test is not designed to determine protection to Streptococcus pneumoniae based on a single specimen.
CPT Code(s)
86317 x9
Component Test Code*Component Chart NameLOINC
0050719Pneumo Serotype Interpretation42771-6
2005780Pneumococcal Serotype 2 IgG40964-9
2005781Pneumococcal Serotype 10A IgG40967-2
2005782Pneumococcal Serotype 11A IgG40968-0
2005783Pneumococcal Serotype 15B IgG40973-0
2005784Pneumococcal Serotype 17F IgG40963-1
2005785Pneumococcal Serotype 19A IgG40974-8
2005786Pneumococcal Serotype 20 IgG40965-6
2005787Pneumococcal Serotype 22F IgG40966-4
2005788Pneumococcal Serotype 33F IgG40969-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.